An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
IgA nephropathy remains the most common primary glomerular disease worldwide. It affects children and adults of all ages, and is a leading cause of end-stage kidney disease, making it a considerable public health issue in many countries. Despite being initially described over 50 years ago, there are...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/11/2493 |
| _version_ | 1797531314956533760 |
|---|---|
| author | Chee Kay Cheung Arun Rajasekaran Jonathan Barratt Dana V. Rizk |
| author_facet | Chee Kay Cheung Arun Rajasekaran Jonathan Barratt Dana V. Rizk |
| author_sort | Chee Kay Cheung |
| collection | DOAJ |
| description | IgA nephropathy remains the most common primary glomerular disease worldwide. It affects children and adults of all ages, and is a leading cause of end-stage kidney disease, making it a considerable public health issue in many countries. Despite being initially described over 50 years ago, there are still no disease specific treatments, with current management for most patients being focused on lifestyle measures and renin-angiotensin-aldosterone system blockade. However, significant advances in the understanding of its pathogenesis have been made particularly over the past decade, leading to great interest in developing new therapeutic strategies, and a significant rise in the number of interventional clinical trials being performed. In this review, we will summarise the current state of management of IgAN, and then describe major areas of interest where new therapies are at their most advanced stages of development, that include the gut mucosal immune system, B cell signalling, the complement system and non-immune modulators. Finally, we describe clinical trials that are taking place in each area and explore future directions for translational research. |
| first_indexed | 2024-03-10T10:42:01Z |
| format | Article |
| id | doaj.art-742c0b4146c2419abd4d58fa68c8cd91 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T10:42:01Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-742c0b4146c2419abd4d58fa68c8cd912023-11-21T22:52:06ZengMDPI AGJournal of Clinical Medicine2077-03832021-06-011011249310.3390/jcm10112493An Update on the Current State of Management and Clinical Trials for IgA NephropathyChee Kay Cheung0Arun Rajasekaran1Jonathan Barratt2Dana V. Rizk3Department of Cardiovascular Sciences, University of Leicester, Leicester LE1 7RH, UKDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, ZRB 614, 1720 2nd Avenue South, Birmingham, AL 35294, USADepartment of Cardiovascular Sciences, University of Leicester, Leicester LE1 7RH, UKDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, ZRB 614, 1720 2nd Avenue South, Birmingham, AL 35294, USAIgA nephropathy remains the most common primary glomerular disease worldwide. It affects children and adults of all ages, and is a leading cause of end-stage kidney disease, making it a considerable public health issue in many countries. Despite being initially described over 50 years ago, there are still no disease specific treatments, with current management for most patients being focused on lifestyle measures and renin-angiotensin-aldosterone system blockade. However, significant advances in the understanding of its pathogenesis have been made particularly over the past decade, leading to great interest in developing new therapeutic strategies, and a significant rise in the number of interventional clinical trials being performed. In this review, we will summarise the current state of management of IgAN, and then describe major areas of interest where new therapies are at their most advanced stages of development, that include the gut mucosal immune system, B cell signalling, the complement system and non-immune modulators. Finally, we describe clinical trials that are taking place in each area and explore future directions for translational research.https://www.mdpi.com/2077-0383/10/11/2493IgAIgA nephropathyclinical trials |
| spellingShingle | Chee Kay Cheung Arun Rajasekaran Jonathan Barratt Dana V. Rizk An Update on the Current State of Management and Clinical Trials for IgA Nephropathy Journal of Clinical Medicine IgA IgA nephropathy clinical trials |
| title | An Update on the Current State of Management and Clinical Trials for IgA Nephropathy |
| title_full | An Update on the Current State of Management and Clinical Trials for IgA Nephropathy |
| title_fullStr | An Update on the Current State of Management and Clinical Trials for IgA Nephropathy |
| title_full_unstemmed | An Update on the Current State of Management and Clinical Trials for IgA Nephropathy |
| title_short | An Update on the Current State of Management and Clinical Trials for IgA Nephropathy |
| title_sort | update on the current state of management and clinical trials for iga nephropathy |
| topic | IgA IgA nephropathy clinical trials |
| url | https://www.mdpi.com/2077-0383/10/11/2493 |
| work_keys_str_mv | AT cheekaycheung anupdateonthecurrentstateofmanagementandclinicaltrialsforiganephropathy AT arunrajasekaran anupdateonthecurrentstateofmanagementandclinicaltrialsforiganephropathy AT jonathanbarratt anupdateonthecurrentstateofmanagementandclinicaltrialsforiganephropathy AT danavrizk anupdateonthecurrentstateofmanagementandclinicaltrialsforiganephropathy AT cheekaycheung updateonthecurrentstateofmanagementandclinicaltrialsforiganephropathy AT arunrajasekaran updateonthecurrentstateofmanagementandclinicaltrialsforiganephropathy AT jonathanbarratt updateonthecurrentstateofmanagementandclinicaltrialsforiganephropathy AT danavrizk updateonthecurrentstateofmanagementandclinicaltrialsforiganephropathy |